Cloning Concerns
By Richard Hayes,
Washington Post
| 11. 24. 2007
As the Nov. 21 front-page article "Advance May End Stem Cell Debate" implied, religious conservatives are not the only ones concerned about the use of human cloning for stem cell research. Many liberals, progressives and supporters of women's health and reproductive rights are uneasy for reasons of their own.
Cloning-based stem cell therapies have been projected to cost upward of $100,000 per treatment, raising questions of health equity and access.
Cloning for stem cell research opens the door to reproductive cloning and to high-tech eugenic and "designer baby" applications. And millions of women's eggs would be needed each year to supply the proposed cloning-based "personalized medicine" industry.
With this week's stem cell breakthroughs, the embryo wars may be behind us. Liberals are now in a position to take the lead in drawing attention to the social justice and human rights concerns that the new human genetic technologies raise.
RICHARD HAYES
Executive Director
Center for Genetics and Society
Oakland, Calif.
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024